Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

General and administrative expense for the year ended December 31, 2024 increased to $4.7 million, compared to $4.2 million for the year ended December 31, 2023 primarily due to increased salaries and ...

Charles Schwab Investment Management Inc. bought a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Free ...

Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce ...

Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio ...

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...

Research analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for Bolt Biotherapeutics in a report issued on Tuesday, March 25th. Leerink Partnrs analyst D. Graybosch ...

Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...